Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
| Autor: | Maurie Markman, Ian Abramson, Stephen B. Howell, Stephen Cleary, William E. Lucas, Soloman Zimm, Regis J. Weiss |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Risk Oncology Cancer Research medicine.medical_specialty Disease Gastroenterology Bleomycin Refractory Actuarial Analysis Ovarian carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Long term survival medicine Humans Survival analysis Aged Aged 80 and over Ovarian Neoplasms Cisplatin business.industry Small volume Cytarabine Obstetrics and Gynecology Combination chemotherapy General Medicine Middle Aged Surgery Doxorubicin Drug Evaluation Female business Injections Intraperitoneal Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 5:1607-1612 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1987.5.10.1607 |
| Popis: | Ninety ovarian carcinoma patients failing primary intravenous (IV) combination chemotherapy were treated with cisplatin-based combination intraperitoneal therapy. Sixty-five patients had residual disease greater than 2 cm at the start of intraperitoneal therapy. Their median survival was 8 months. Twenty-five patients had disease less than 2 cm; their median survival was greater than 49 months, and the survival curve has an apparent plateau at 69%, with no relapses having occurred after 32 months. The median survival for all 90 patients was 15 months. The median duration of follow-up for all patients was 37 months. These results confirm the critical role of tumor bulk in determining the effectiveness of intraperitoneal therapy, and suggest a role for intraperitoneal salvage treatment in patients with small-volume disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|